Back

Beta-blocker therapy and sexual dysfunction after myocardial infarction: a sub-study of the BETAMI-DANBLOCK trial

31 August 2026 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Contemporary beta‑blocker pharmacotherapy Beta-Blockers ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mrs Johanne Elise Nyen

Drammen Hospital, Drammen (Norway)

7 More presentations in this session

Presentation thumbnail
Metoprolol versus bisoprolol in patients with acute myocardial infarction: a target trial emulation study
Doctor T. Yang (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
β-blocker adherence trajectories and 5-year clinical outcomes in PCI-treated ACS patients with LVEF ≥50%: a group-based trajectory modeling analysis
Professor M. Qiu (Shenyang, CN)
Abstract Slides Video
Presentation thumbnail
In-hospital beta-blocker initiation is associated with improved survival in AF-HFpEF with tachycardia
Doctor S. Naito (JP)
Abstract Slides Video
Presentation thumbnail
Beta-blocker therapy after myocardial infarction in the PCI Era: an updated meta-analysis
Doctor J. Aleman (Cebu City, PH)
Abstract Slides Video
Presentation thumbnail
The range of left ventricular ejection fraction associated with survival benefit from beta-blockers
Professor J. Choi (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Contemporary beta‑blocker pharmacotherapy

The Event

Event poster

ESC Congress 2026

31 August 2026 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Beta-blocker therapy and angina pectoris after myocardial infarction: a BETAMI-DANBLOCK substudy
23 April 2026
thumbnail
Congress Presentation
Sexual functioning after the age of 40 in adults with moderate or severe congenital heart disease
31 August 2025
thumbnail
Congress Presentation
Gender differences in the treatment of heart failure with reduced ejection fraction
29 June 2021
thumbnail
Congress Presentation
Determinants of erectile dysfunction in the early phase after percutaneous coronary intervention: a prospective comparative analysis
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources